[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 12/18/2017 – 12/22/2017:

1) CRIS – Curis, Inc.
a. Buy at < ~ $0.76
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 2 – Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02674750
2. Phase 1 – Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT01742988
3. Phase 1 update from CUDC-907, CA-170 and potential additional programs; 2016; ; https://finance.yahoo.com/news/curis-present-bio-ceo-investor-210500148.html
4. Phase 1 – A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT03328078
5. Phase 1 – Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma; 20191001; 20221031; https://ClinicalTrials.gov/show/NCT02909777
6. Phase 1 – A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas; 20190101; 20200131; https://ClinicalTrials.gov/show/NCT02812875

2) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx

3) MBOT – Microbot Medical Inc
a. Buy at < ~ $1.00
b. Sell at >~ $1.50

4) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02740868

5) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.20

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 12/18/2017 - 12/22/2017, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 12/08/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.99
2. $EGLT – Egalet Corp :
   1. Cash/sh = $1.95
3. $FCSC – Fibrocell Science Inc :
   1. Cash/sh = $1.35
4. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.46
5. $ROKA – Sorrento Tech Inc :
   1. Cash/sh = $3.18
6. $VVUS – VIVUS, Inc. :
   1. Cash/sh = $2.23

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 12/11/2017 – 12/15/2017:

1) CRIS – Curis, Inc.
a. Buy at < ~ $0.79
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 2 – Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02674750
2. Phase 1 – Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT01742988
3. Phase 1 update from CUDC-907, CA-170 and potential additional programs; 2016; ; https://finance.yahoo.com/news/curis-present-bio-ceo-investor-210500148.html
4. Phase 1 – A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT03328078
5. Phase 1 – Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma; 20191001; 20221031; https://ClinicalTrials.gov/show/NCT02909777
6. Phase 1 – A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas; 20190101; 20200131; https://ClinicalTrials.gov/show/NCT02812875

2) PERI – Perion Network Ltd
a. Buy at < ~ $0.94
b. Sell at >~ $2.00

3) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx

4) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02740868

5) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.20

6) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.38
b. Sell at >~ $1.80

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 12/11/2017 – 12/15/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 12/04/2017 – 12/08/2017:

1) CRIS – Curis, Inc.
a. Buy at < ~ $0.79
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 2 – Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02674750
2. Phase 1 – Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT01742988
3. Phase 1 update from CUDC-907, CA-170 and potential additional programs; 2016; ; https://finance.yahoo.com/news/curis-present-bio-ceo-investor-210500148.html
4. Phase 1 – A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT03328078
5. Phase 1 – Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma; 20191001; 20221031; https://ClinicalTrials.gov/show/NCT02909777
6. Phase 1 – A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas; 20190101; 20200131; https://ClinicalTrials.gov/show/NCT02812875

2) RWLK – Rewalk Robotics Ltd
a. Buy at < ~ $1.05
b. Sell at >~ $3.20

3) ABIL – Ability Inc
a. Buy at < ~ $0.44
b. Sell at >~ $1.00

4) PERI – Perion Network Ltd
a. Buy at < ~ $0.94
b. Sell at >~ $2.00

5) ONTX – Onconova Therapeutics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $2.80
c. Catalysts:
1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
2. Phase 3 enrolling. Interim analysis due 4Q 2017. Noted August 15, 2017 that enrollment has been slower than expected. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20171231; 20171231; http://investor.onconova.com/releasedetail.cfm?ReleaseID=1037302
3. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
4. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm
5. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
6. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
7. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
9. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
10. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725

6) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx

7) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02740868

8) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.20

9) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $0.80
b. Sell at >~ $1.05
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 12/04/2017 – 12/08/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 11/23/2017 include:

1. $HEB – Hemispherx BioPharma, Inc :
   1. Book/sh = $0.51
2. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $21.56
3. $ROKA – Sorrento Tech Inc :
   1. Book/sh = $5.93
4. $ROSG – Rosetta Genomics Ltd. (USA) :
   1. Book/sh = $2.40

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 11/23/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.99
2. $EGLT – Egalet Corp :
   1. Cash/sh = $1.95
3. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.46
4. $ROKA – Sorrento Tech Inc :
   1. Cash/sh = $3.18
5. $VVUS – VIVUS, Inc. :
   1. Cash/sh = $2.23

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

Here is another IMHO Must Read Article(s) for Traders:

“Focus: What Distinguishes Trading Professionals From Amateurs” => https://traderfeed.blogspot.com/2017/10/focus-what-distinguishes-trading.html

What do you all think about all of that?

Let’s talk about it all herein, ok?

I hope this helps! Good Luck! and Have a Great Trading Week!

– Michael S. DeVries

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 11/20/2017 – 11/24/2017:

1) RWLK – Rewalk Robotics Ltd
a. Buy at < ~ $1.05
b. Sell at >~ $3.20

2) PERI – Perion Network Ltd
a. Buy at < ~ $0.94
b. Sell at >~ $2.00

3) SGYP – Synergy Pharmaceuticals Inc
a. Buy at < ~ $1.68
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 3 – A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma; 20171201; 20211231; https://ClinicalTrials.gov/show/NCT02409186
2. Phase 1 – ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer; 20180101; 20190131; https://ClinicalTrials.gov/show/NCT02632071
3. NA – Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT02770651
4. NA – Xience Versus Synergy in Left Main PCI; 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02303717
5. Phase 3 data from first and second trials met primary endpoints – December 9 and 22, 2016. PDUFA date January 24, 2018. – Trulance (plecanatide) – Constipation-predominant irritable bowel syndrome (IBS-C) – PDUFA; 20180124; 20180124; http://ir.synergypharma.com/press-releases/detail/1850
6. NA – Ulcerative Colitis Relapse Prevention by Prebiotics; 20180501; 20181031; https://ClinicalTrials.gov/show/NCT02865707
7. Phase 4 – Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT; 20180501; 20190501; https://ClinicalTrials.gov/show/NCT03112707
8. NA – Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy; 20180401; 20181130; https://ClinicalTrials.gov/show/NCT02594501
9. Phase 2 – Proteasome Inhibition in Acute Promyelocytic Leukemia; 20180501; 20180531; https://ClinicalTrials.gov/show/NCT01950611
10. Phase 1 – Cancer Stem Cell High-Throughput Drug Screening Study; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT02654964
11. Phase 4 – Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome; 20151001; 20191031; https://ClinicalTrials.gov/show/NCT02049229
12. NA – Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT); 20160824; 20190831; https://ClinicalTrials.gov/show/NCT01674803
13. Phase 3 – The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s); 20140901; 20180831; https://ClinicalTrials.gov/show/NCT01665053
14. NA – The OCT SORT-OUT VIII Study; 20150401; 20251231; https://ClinicalTrials.gov/show/NCT02253108
15. Phase 1Phase 2 – Daratumumab in Combination With ATRA; 20170501; 20180531; https://ClinicalTrials.gov/show/NCT02751255
16. NA – Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment; 20170701; 20190228; https://ClinicalTrials.gov/show/NCT02727582
17. Phase 2 – Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma; 20171001; 20210430; https://ClinicalTrials.gov/show/NCT02437812
18. Phase 4 – Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.; 20170501; 20180630; https://ClinicalTrials.gov/show/NCT02099617
19. Phase 4 – Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction; 20170701; 20180731; https://ClinicalTrials.gov/show/NCT02890589
20. Phase 4 – Optimization of Antiretroviral Therapy; 20180601; 20181231; https://ClinicalTrials.gov/show/NCT02935075
21. Phase 1 – Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients; 20190701; 20190701; https://ClinicalTrials.gov/show/NCT02152943
22. Phase 1 – Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance; 20190901; 20190930; https://ClinicalTrials.gov/show/NCT01197170
23. Phase 1Phase 2 – Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients; 20190501; 20190531; https://ClinicalTrials.gov/show/NCT02906800
24. NA – MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial; 20190601; 20191231; https://ClinicalTrials.gov/show/NCT03135275
25. Phase 4 – DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT03208907
26. Phase 3 – Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry; 20210630; 20211230; https://ClinicalTrials.gov/show/NCT03048825
27. NA – Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice; 20251201; 20251231; https://ClinicalTrials.gov/show/NCT01186133
28. Phase 1 – Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor; 20200831; 20240831; https://ClinicalTrials.gov/show/NCT03239145
29. NA – IRIS-Synergy Cohort in the IRIS-DES Registry; 20201201; 20250630; https://ClinicalTrials.gov/show/NCT02720419
30. Phase 4 – EVOLVE Short DAPT Study; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02605447
31. Phase 2 – An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation; 20180901; 20180930; https://ClinicalTrials.gov/show/NCT03120520
32. Phase 2 – Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY); 20180901; 20181031; https://ClinicalTrials.gov/show/NCT03018340
33. Phase 1Phase 2 – MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas; 20180630; 20191231; https://ClinicalTrials.gov/show/NCT02311582
34. Phase 1 – Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00708448
35. Phase 2 – CyBeR Association in Relapsed/Refractory DLBCL; 20181101; 20181231; https://ClinicalTrials.gov/show/NCT02758925
36. Early Phase 1 – Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia; 20190101; 20210131; https://ClinicalTrials.gov/show/NCT02621944
37. Phase 1 – A Study of APG-1252 in Patients With SCLC or Other Solid Tumors; 20190212; 20190212; https://ClinicalTrials.gov/show/NCT03080311
38. Phase 1 – Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma; 20181117; 20191117; https://ClinicalTrials.gov/show/NCT03233152
39. Phase 2Phase 3 – Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT02111798

4) ABIL – Ability Inc
a. Buy at < ~ $0.50
b. Sell at >~ $1.00

5) GNCA – Genocea Biosciences Inc
a. Buy at < ~ $1.03
b. Sell at >~ $2.00
c. Catalysts:
1. Q4 2017 Genocea Biosciences Inc Earnings Release (Estimated); 20180214; 20180214; https://www.google.com/finance?q=GNCA
2. Phase 2 – Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection; 20180630; 20180630; https://ClinicalTrials.gov/show/NCT03146403
3. NA – Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02910284

6) ONTX – Onconova Therapeutics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $2.80
c. Catalysts:
1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
2. Phase 3 enrolling. Interim analysis due 4Q 2017. Noted August 15, 2017 that enrollment has been slower than expected. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20171231; 20171231; http://investor.onconova.com/releasedetail.cfm?ReleaseID=1037302
3. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
4. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm
5. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
6. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
7. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
9. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
10. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725

7) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx

8) MBOT – Microbot Medical Inc
a. Buy at < ~ $1.00
b. Sell at >~ $1.50

9) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.10
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02740868

10) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.20

11) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $0.80
b. Sell at >~ $1.05
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. Q2 2018 Oasmia Pharmaceutical AB Earnings Release (Estimated); 20171130; 20171130; https://www.google.com/finance?q=OASM

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 11/20/2017 – 11/24/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 11/13/2017 – 11/17/2017:

1) PERI – Perion Network Ltd
a. Buy at < ~ $0.94
b. Sell at >~ $2.00

2) GNCA – Genocea Biosciences Inc – Trading Below Cash
a. Buy at < ~ $1.03
b. Sell at >~ $2.00
c. Catalysts:
1. Phase 2 – Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection; 20180630; 20180630; https://ClinicalTrials.gov/show/NCT03146403
2. NA – Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02910284

3) ABIL – Ability Inc
a. Buy at < ~ $0.57
b. Sell at >~ $1.00

4) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx

5) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.10
b. Sell at >~ $1.75

6) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.25
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02740868
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255

7) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.20

8) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $0.80
b. Sell at >~ $1.05
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. Q2 2018 Oasmia Pharmaceutical AB Earnings Release (Estimated); 20171130; 20171130; https://www.google.com/finance?q=OASM

9) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.38
b. Sell at >~ $1.80

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 11/13/2017 – 11/17/2017, and Why?

[Michael DeVries]

Here’s some more IMHO Must Read Articles for Traders …

1. 10 Critical Rules for Investing => https://chartyourtrade.com/10-critical-rules-for-investing/
2. How we can master the frustration and anger that can spill over into our #tradingpsychology: https://traderfeed.blogspot.com/2017/11/trading-psychology-challenges-4.html
3. Why does our trading become inconsistent, and what can we do about that? => https://traderfeed.blogspot.com/2017/11/trading-psychology-challenges-3.html

What do you all think about all of those?

Let’s talk about them all herein, ok?

I hope this helps! Good Luck! and Have a Great Day!

– Michael S. DeVries

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 10/27/2017 include:

1. $EVAR – Lombard Medical Inc :
   1. Book/sh = $0.89
2. $HEB – Hemispherx BioPharma, Inc :
   1. Book/sh = $0.51
3. $MICT – Micronet Enertec Technologies Inc :
   1. Book/sh = $0.80
4. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $21.42
5. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
6. $ROSG – Rosetta Genomics Ltd. (USA) :
   1. Book/sh = $2.40

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/30/2017 – 11/03/2017:

1) CEMP – Cempra Inc – Trading Below Cash
a. Buy at < ~ $2.05
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 2Phase 3 – Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated; 20171001; 20181231; https://ClinicalTrials.gov/show/NCT02569541
2. Phase 2/3 data due by the end of 2017. – Taksta – Fusidic acid – Refractory infections in bones and joints – Phase 2/3; 20171231; 20171231; http://investor.cempra.com/secfiling.cfm?filingid=1193125-17-252119&CIK=1461993
3. Phase 2Phase 3 – Safety and Efficacy of Solithromycin in Adolescents and Children With Community-acquired Bacterial Pneumonia; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02605122

2) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $0.97
b. Sell at >~ $1.54
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

3) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.38
b. Sell at >~ $1.80
c. Catalysts:
1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
-; 20171101; 20171101; https://www.google.com/finance?q=ONVO

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/30/2017 – 11/03/2017, and Why?

[Michael DeVries]

The following is, what I believe, an article(s) relative to this Topic:

“Wall Street’s Robots Still Have a Lot to Learn About Being a Human Trader” => https://www.bloomberg.com/news/articles/2017-10-19/coders-who-trade-wall-street-designs-its-staff-for-the-future

What do you think about all of that?

Let’s Discuss it all herein, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 10/20/2017 include:

1. $HEB – Hemispherx BioPharma, Inc :
   1. Book/sh = $0.51
2. $MICT – Micronet Enertec Technologies Inc :
   1. Book/sh = $0.80
3. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $21.86
4. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
5. $ROSG – Rosetta Genomics Ltd. (USA) :
   1. Book/sh = $2.40

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 10/20/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.00
2. $EGLT – Egalet Corp :
   1. Cash/sh = $2.03
3. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.48
4. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $2.84
5. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $3.54
6. $VVUS – VIVUS, Inc. :
   1. Cash/sh = $2.39

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/23/2017 – 10/27/2017:

1) ARTW – Arts-Way Manufacturing Co. Inc.
a. Buy at < ~ $2.40
b. Sell at >~ $3.50

2) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.38
b. Sell at >~ $1.80
c. Catalysts:
1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
-; 20171101; 20171101; https://www.google.com/finance?q=ONVO

3) EVAR – Lombard Medical Inc
a. Buy at < ~ $0.40
b. Sell at >~ $0.50
c. Catalysts:
1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/23/2017 – 10/27/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/16/2017 – 10/20/2017:

1) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.60
b. Sell at >~ $4.99
c. Catalysts:
1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
-; 20171101; 20171101; https://www.google.com/finance?q=ONVO

2) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $1.01
b. Sell at >~ $1.59
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

3) VVUS – VIVUS, Inc. – Trading Below Cash
a. Buy at < ~ $0.86
b. Sell at >~ $1.30
c. Catalysts:
1. Q3 2017 VIVUS Inc Earnings Release (Estimated)
-; 20171107; 20171107; https://www.google.com/finance?q=VVUS
2. Phase 2 – Qsymia as an Adjunct to Surgical Therapy in the Superobese; 20171201; 20171231; https://ClinicalTrials.gov/show/NCT02301416

4) ROSG – Rosetta Genomics Ltd. (USA)
a. Buy at < ~ $0.98
b. Sell at >~ $1.40
c. Catalysts:
1. The sale of PDx is expected to close within the next several weeks; 20170908; 20171231; https://finance.yahoo.com/news/rosetta-genomics-enters-agreement-sell-123000567.html

5) ARTW – Arts-Way Manufacturing Co. Inc.
a. Buy at < ~ $2.40
b. Sell at >~ $3.50

6) EVAR – Lombard Medical Inc – Trading Below Cash
a. Buy at < ~ $0.40
b. Sell at >~ $0.50
c. Catalysts:
1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/16/2017 – 10/20/2017, and Why?

[Michael DeVries]

10 Trading Rules For New & Aspiring Traders => https://www.seeitmarket.com/top-10-trading-rules-for-new-aspiring-traders-16184/

What do you all think about all of these Trading Rules?

What other Trading Rules would your Recommend for New and Aspiring Traders?

I hope this helps! Good Luck! and Have a Great Day!

– Michael S. DeVries

[Michael DeVries]

This film explains what high frequency trading is, how it affects the financial markets, what negative impact it has and how to regulate it =>

I hope that you find it helpful as well (?)

What do you all think about all of this?

Let’s discuss it all herein, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/09/2017 – 10/13/2017:

1) ROSG – Rosetta Genomics Ltd. (USA)
a. Buy at < ~ $0.98
b. Sell at >~ $1.40
c. Catalysts:
1. The sale of PDx is expected to close within the next several weeks; 20170908; 20171231; https://finance.yahoo.com/news/rosetta-genomics-enters-agreement-sell-123000567.html

2) ARTW – Arts-Way Manufacturing Co. Inc.
a. Buy at < ~ $2.40
b. Sell at >~ $3.50

3) ONTX – Onconova Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.50
b. Sell at >~ $1.99
c. Catalysts:
1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
2. Phase 3 enrolling. Interim analysis due 4Q 2017. Noted August 15, 2017 that enrollment has been slower than expected. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20171231; 20171231; http://investor.onconova.com/releasedetail.cfm?ReleaseID=1037302
3. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
4. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm
5. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
6. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
7. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
9. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
10. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725

4) EVAR – Lombard Medical Inc – Trading Below Cash
a. Buy at < ~ $0.40
b. Sell at >~ $0.50
c. Catalysts:
1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/09/2017 – 10/13/2017, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 10/01/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.00
3. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
4. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.80
5. $LBIX – Leading Brands, Inc (USA) :
   1. Cash/sh = $0.98
6. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.44
7. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.69
8. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $1.68
9. $RTTR – Ritter Pharmaceuticals Inc :
   1. Cash/sh = $0.42
10. $TNXP – Tonix Pharmaceuticals Holding Corp. :
    1. Cash/sh = $4.67

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

‘Stages Of a Trader’, by Bo Yoder => http://theimpatienttrader.blogspot.com/2017/09/stages-of-trader-by-bo-yoder.html

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 09/01/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Book/sh = $3.00
3. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.73
4. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.19
5. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $22.22
6. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $2.44

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 09/01/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.95
3. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Cash/sh = $1.93
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
5. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.85
6. $EGLT – Egalet Corp :
   1. Cash/sh = $2.30
7. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.44
8. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $1.68

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 09/05/2017 – 09/08/2017:

1) OTIC – Otonomy Inc – Trading Below Cash
a. Buy at < ~ $3.30
b. Sell at >~ $10.50
c. Catalysts:
1. Phase 3 – Study of OTO-104 in Subjects With Unilateral Menieres Disease; 20171101; 20171130; https://ClinicalTrials.gov/show/NCT02717442
2. Q3 2017 Otonomy Inc Earnings Release (Estimated)
-; 20171101; 20171101; https://www.google.com/finance?q=OTIC
3. Phase 2 – Open Label Study of OTO-104 in Subjects With Menieres Disease; 20171001; 20171031; https://ClinicalTrials.gov/show/NCT02740387
4. Phase 3 trial met primary endpoint – January 5, 2017. PDUFA date for sNDA filing March 2, 2018. – OTIPRIO – Acute otitis externa – Phase 3; 20180302; 20180302; http://investors.otonomy.com/phoenix.zhtml?c=234082&p=irol-newsArticle_Print&ID=2286970
5. Phase 2 – Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss; 20180301; 20180630; https://ClinicalTrials.gov/show/NCT02997189
6. Phase 3 – A 6-Month Extension Study of OTO-104 in Menieres Disease; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02706730

2) HEB – Hemispherx BioPharma, Inc
a. Buy at < ~ $0.36
b. Sell at >~ $0.75
c. Catalysts:
1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

3) ONCS – OncoSec Medical Inc
a. Buy at < ~ $0.88
b. Sell at >~ $1.30
c. Catalysts:
1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
2. Q4 2017 OncoSec Medical Inc Earnings Release (Estimated)
-; 20171011; 20171011; https://www.google.com/finance?q=ONCS
3. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

4) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.10
b. Sell at >~ $1.38

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 09/05/2017 – 09/08/2017, and Why?

[Author]

Posts